4 Healthcare Stock Stories For Thursday Investment Wellness

GlaxoSmithKline (NYSE:GSK): Closing price $51.63

GlaxoSmithKline initiated a $50-million strategic venture capital fund on Thursday, increasing its bet on employing electrical signals in the body to target diseases. The United Kingdom drug maker hopes to have the first medicine that effectively speaks the electrical “language” of the body ready for approval by the end of the decade. GSK said the new fund’s first investment would be in the California firm SetPoint Medical, which is working on implantable devices through which to treat inflammatory diseases.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

gsk-08082013

Sanofi-Aventis (NYSE:SNY): Closing price $52.86

An unnamed whistle-blower claims that Sanofi gave around $276,000 in bribes to 503 doctors in China, according to the 21st Century Business Herald. The person, who gave materials to the newspaper, used the pseudonym “bacon” and refused to give his identity, said Thursday’s report, which also related that the bribes were termed as “research spending” in Beijing, Shanghai, Hangzhou, and Guangzhou around November of 2007. Sanofi’s Shanghai-based senior communications manager Clare Xu, said that she could not immediately respond to the report when contacted by Bloomberg News.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

sny-08082013

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP): Current price $5.99

On Thursday, Sucampo announced positive top-line results of two recently completed clinical trials, a Phase 1a trial of cobiprostone, and a Phase 1a trial of SPI-3608. The evaluations tested the tolerability and pharmacokinetic profiles compared to placebo, of the two compounds, both of which were shown to be generally well-tolerated in the tested populations. Cobiprostone is being examined for the prevention and/or treatment of oral mucositis. The Phase 1a clinical trial for the investigational oral spray formulation of cobiprostone showed that the drug is generally well-tolerated in healthy volunteers. A Phase 1b trial should start in the fourth quarter.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

scmp-08082013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA): Closing price $39.14

Teva said Thursday that the European Commission has granted marketing authorization for Lonquex (lipegfilgrastim). This approval gives the regulatory
framework for the commercialization of Lonquex in all twenty eight countries of the European Union, along with Norway, Iceland and Liechtenstein.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

teva-08082013

Don’t Miss: Bad News Obamacare: Americans Lack Insurance Understanding.